Effects of Cytochrome P450 2C9 Polymorphism on Bosentan Metabolism

Bosentan Therapy for Pulmonary Arterial Hypertension

Lewis J. Rubin, David B. Badesch, Robyn J. Barst et al. · New England Journal of Medicine · 2002 · 2.7K citations · Full text

Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.

Martine Clozel, Volker Breu, Gillian A. Gray et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 667 citations

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects

Cornelia Weber, Rita Schmitt, Herbert Birnboeck et al. · Clinical Pharmacology & Therapeutics · 1996 · 204 citations

Roles of Human Hepatic Cytochrome P450s 2C9 and 3A4 in the Metabolic Activation of Diclofenac

Wei Tang, Ralph A. Stearns, Regina W. Wang et al. · Chemical Research in Toxicology · 1999 · 154 citations

Metabolic Activation, Metabolomic Profiling, Pharmacotherapy +18

Discovery of new potentially defective alleles of human CYP2C9

Joyce Blaisdell, Lucia F. Jorge-Nebert, Sherry J. Coulter et al. · Pharmacogenetics · 2004 · 142 citations

Crystal Structure, Allelic Variant, Human Cyp2c9 +13